VivoSim Labs financials
$0.2025−8.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 |
|---|---|
| Revenue | $131.0K |
| Gross profit | $131.0K |
| Gross margin | 100.0% |
| Operating income | -$11.5M |
| Net income | -$13.8M |
| Net margin | −10567.2% |
| Diluted EPS | $-5.35 |
| EBITDA | -$11.3M |
| Operating cash flow | -$10.8M |
| Free cash flow | -$10.8M |
| Diluted shares | 2.6M |
Balance sheet
| Period end | Mar 31 |
|---|---|
| Cash & equivalents | $5.0M |
| Short-term investments | $0.00 |
| Total debt | $0.00 |
| Total assets | $7.4M |
| Total liabilities | $8.5M |
| Shareholders' equity | -$1.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology